229 related articles for article (PubMed ID: 35745789)
1. Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study.
Escudero-Ortiz V; Domínguez-Leñero V; Catalán-Latorre A; Rebollo-Liceaga J; Sureda M
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745789
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
4. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD
Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
[TBL] [Abstract][Full Text] [Related]
6. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
7. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
[TBL] [Abstract][Full Text] [Related]
8. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring.
Noda S; Morita SY; Terada T
Biol Pharm Bull; 2022; 45(7):814-823. PubMed ID: 35786588
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.
Guchelaar NAD; van Eerden RAG; Groenland SL; Doorn LV; Desar IME; Eskens FALM; Steeghs N; van Erp NP; Huitema ADR; Mathijssen RHJ; Koolen SLW;
Biomed Pharmacother; 2022 Sep; 153():113393. PubMed ID: 35834987
[TBL] [Abstract][Full Text] [Related]
10. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
[TBL] [Abstract][Full Text] [Related]
11. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
[TBL] [Abstract][Full Text] [Related]
12. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring and tyrosine kinase inhibitors.
Herviou P; Thivat E; Richard D; Roche L; Dohou J; Pouget M; Eschalier A; Durando X; Authier N
Oncol Lett; 2016 Aug; 12(2):1223-1232. PubMed ID: 27446421
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
Henriksen JN; Andersen CU; Fristrup N
Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
[TBL] [Abstract][Full Text] [Related]
15. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
Couchman L; Birch M; Ireland R; Corrigan A; Wickramasinghe S; Josephs D; Spicer J; Flanagan RJ
Anal Bioanal Chem; 2012 Jun; 403(6):1685-95. PubMed ID: 22526649
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Andriamanana I; Gana I; Duretz B; Hulin A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis.
Paech F; Bouitbir J; Krähenbühl S
Front Pharmacol; 2017; 8():367. PubMed ID: 28659801
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of tyrosine kinase inhibitors.
van Erp NP; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
Ther Drug Monit; 2014 Jun; 36(3):317-25. PubMed ID: 24365980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
